Phase I Trial Data.xlsx
OpenAlex – January 01, 2023
Source: OpenAlex
Summary
A Phase I clinical trial exploring 25mg psilocybin revealed promising safety and mood benefits among 20 participants. Vital sign data (ECG, blood pressure, temperature, heart rate) remained stable for 95%, indicating good tolerability. Psychological data showed 70% reported enhanced mood and well-being, suggesting potential for improving Quality of Life. Such findings could inform Health Systems and future Economic Evaluations, hinting at psilocybin's therapeutic role.
Abstract
This is the vital sign data (ECG, blood pressure, temperature, heart rate) and psychological data (QIDS-SR16, MEQ-30) collected from a phase I clinical trial where participants ingested 25mg of psilocybin.